Autor: |
Hampel, B, Kusejko, K, Kouyos, R D, Böni, J, Flepp, M, Stöckle, M, Conen, A, Béguelin, C, Künzler-Heule, P, Nicca, D, Schmidt, A J, Nguyen, H, Delaloye, J, Rougemont, M, Bernasconi, E, Rauch, A, Günthard, H F, Braun, D L, Fehr, J |
Jazyk: |
angličtina |
Rok vydání: |
2020 |
Předmět: |
|
DOI: |
10.7892/boris.137500 |
Popis: |
OBJECTIVES Chemsex refers to the use of sex-enhancing drugs among men who have sex with men (MSM) in combination with specific sexual and social behaviours. Longitudinal data on this development and the associated health risks are scarce. METHODS Data on all recreational drugs reported in the Swiss HIV Cohort Study (SHCS) from 2007 to 2017 were collected. Drug use was analysed longitudinally for all drug classes. In addition, potential associations between patient characteristics and the consumption of methamphetamine, γ-hydroxybutric acid/γ-butyrolactone (GHB/GBL), 3,4-methylenedioxymethamphetamine (MDMA/XTC), cocaine and amphetamine were analysed. RESULTS We analysed 166 167 follow-up entries for 12 527 SHCS participants, including 7101 free text field entries containing information about recreational drugs other than cannabis, cocaine and heroin. Overall, we observed a stable percentage (9.0%) of recreational drug use (excluding cannabis, amyl nitrite and prescription drugs). For MSM, however, there was an increase in overall drug use from 8.8% in 2007 to 13.8% in 2017, with particularly large increases for methamphetamine (from 0.2 to 2.4%; P |
Databáze: |
OpenAIRE |
Externí odkaz: |
|